// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:← Back to module
B
Tumor mutational burden (TMB) predicts checkpoint-inhibitor response across all solid tumors
Validated in NSCLC, melanoma, MSI-H/dMMR; pan-tumor cutoffs (≥10 mut/Mb) are imperfect.
Module 05 · Cancer Genomics: Germline, Somatic, and Liquid →